Add time:08/20/2019         Source:sciencedirect.com

About 30% of the patients with epilepsy do not respond to clinically established anticonvulsants, despite having effective concentrations of the antiepileptic drug in plasma. Therefore, new preclinical models of epilepsy are needed to identify more efficacious treatments. We describe here a new drug-resistant seizure model in mice to be used at the early stages of pre-clinical trials. This model consists in inducing daily generalized seizures for 23 consecutive days by administration of 3-Mercaptopropionic acid (cas 107-96-0) (MP). As a result, 100% of animals become resistant to phenytoin and 80% to phenobarbital. Such resistance is strongly associated with the overexpression of P-glycoprotein (Pgp), observed in cerebral cortex, hippocampus and striatum while resistance to Pgp nonsubstrate drugs such as carbamazepine, diazepam and levetiracetam is not observed.This model could be useful for screening novel anticonvulsant drugs with a potential effect on pharmacoresistant seizures treatment.

We also recommend Trading Suppliers and Manufacturers of 3-Mercaptopropionic acid (cas 107-96-0). Pls Click Website Link as below: cas 107-96-0 suppliers